Van Helsing

Once again...welcome to my house. Come freely. Go safely; and leave something of the happiness you bring.

[Papa Heme @Papa_Heme]

At this point recommending high dose methotrexate to prevent CNS relapse in DLBCL is worse than recommending ivermectin. https://t.co/6d9j9dtvOX

[Alonzo Solano @DondeAlonzo]

Hay una comodidad inigualable en escuchar a @AlvaroNBAMartin y al coach Morales narrar las finales, es casi nostálgico.

Tardó Amazon, pero llegaron

[Joshúa Maya @PlaysOfTheWeek]

COMEBACK FOR THE AGES!!

[Will Compton @_willcompton]

Man I feel for Jared Verse

• A superstar on a Super Bowl contender
• Coached by one of the best coaches in the NFL
• In LA with an MVP quarterback

And now he’s going to Cleveland

Damn..

[Dan Fetes @danfetes]

The Rams saw a divisional rival, who they were neck-and-neck with, WIN the Super Bowl...

And they went, "F*uck that. We're not letting that happen again."

Garrett, McDuffie, Watson.

[Talha Badar @TalhaBadarMD]

#ASCO26 #leusm #ALL @MDAndersonnews

Long-term follow-up of Hyper-CVAD + sequential blinatumomab ± low-dose fractionated inotuzumab ozogamicin (INO) in newly diagnosed Ph-negative B-ALL demonstrates encouraging outcomes.

🔹 CR: 100% (59/59 evaluable)
🔹 Flow MRD negativity (10⁻⁴): 95%
🔹 NGS MRD negativity (10⁻⁶): 76%
🔹 30-day mortality: 0%

Among patients treated with fractionated INO (n=37), outcomes were notable:
• 3-year EFS 92% vs 74% in the earlier non-INO cohort (p=0.03)
• 3-year OS 100% vs 82% (p=0.007)

While cross-cohort comparisons should be interpreted cautiously, these data support continued evaluation of antibody-based intensification strategies alongside chemotherapy and blinatumomab in frontline Ph-negative B-ALL.

[Van Helsing @ChelisBR]

@Primeroydiez

[Jacob Tobey @JacobRTobey]

Victor Wembanyama in tears after advancing to the NBA Finals!!! @spurs

[Manu Ginobili @manuginobili]

@Spurs_Latam "Venís seguido a este boliche?"

[Van Helsing @ChelisBR]

Después de lograr conseguir boletos contiguos de la NBA en México, ya nada me parece difícil en la vida.

[Van Helsing @ChelisBR]

@Primeroydiez Es inverosímil llamar sobrevalorado al que ha sido el mejor Qb de la liga los últimos 3 a��os. Les quita credibilidad.

[Rogue FitSurgeon @FitSurgeon]

Amable recordatorio:

NO EXISTE LA ESPECIALIDAD DE MEDICINA ESTÉTICA...

La Especialidad es DERMATOLOGIA o CIRUGIA PLASTICA Y ESTETICA..

La medicina estetica son cursillos y diplomados... o sea pinchis nada...

[Dr Rudra Narayan Swain M.D , D.M @rudra09s025]

Important EHA2026 data in UHR LBCL 👇

In this large international retrospective cohort of 1,923 ultra–high-risk LBCL pts, HD-MTX did not reduce CNS relapse.

What makes this clinically relevant: baseline imbalance reflects real-world practice—HD-MTX was preferentially used in pts with renal/adrenal, testicular, ≥3 extranodal sites, and many also received IT MTX during chemo (~50% in HD-MTX arm).

Yet, despite this intensified “current CNS prophylaxis strategy,” CNS relapse remained similar:
Any CNSr: 9.3% vs 8.1%
Isolated CNSr: 5.9% vs 5.7%
This challenges the routine reflex of adding HD-MTX for CNS prophylaxis in UHR LBCL.
The next key question:
Will this still hold true in the Pola-R-CHP era? although POLARIX - did not show lower CNS relapse

#EHA2026 #Lymphoma #DLBCL #CNSRelapse #HDMTX #PolaRCHP #Hematology @Charanpreet_14 @DrGPrakash
@EHA_Hematology

[Benlazar S M A @smbenlazar]

Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management #lymsm
|American Journal of Hematology | Blood Research Journal | Wiley Online Library https://t.co/e8XOikrBDs

[Dr. Chokri Ben Lamine @abouabdrahman0]

For patients starting Lenalidomide, thromboprophylaxis should be guided by the IMWG and NCCN recommendations using validated risk scores such as IMPEDE VTE Score and SAVED Score.

🩸 All patients receiving lenalidomide-based therapy require VTE risk assessment.

🟢 Low Risk
➡️ No or minimal risk factors
➡️ Aspirin 81–100 mg PO daily

🟠 Intermediate/High Risk
➡️ Any of the following:
• Prior VTE
• Obesity
• Immobility
• Central venous catheter
• High-dose dexamethasone
• Anthracycline-containing therapy
• Use of erythropoiesis-stimulating agents
• Active infection
• Cardiac disease
• Recent surgery
• Known thrombophilia

➡️ Preferred prophylaxis:
• Apixaban 2.5 mg PO BID
• Rivaroxaban 10 mg PO daily
• Enoxaparin 40 mg SC daily
• Warfarin (INR 2–3) if other options are unsuitable

🔴 Very High Risk
➡️ Recent VTE or strong thrombophilia
➡️ Therapeutic anticoagulation may be required.

⏳ Duration
➡️ Continue while receiving lenalidomide-based therapy or until risk factors resolve.

⚠️ Hold prophylaxis if:
• Platelets <50 × 10⁹/L (individualize)
• Active bleeding
• Severe coagulopathy

💎 Clinical Pearl
Lenalidomide + dexamethasone substantially increases VTE risk; aspirin is acceptable only for truly low-risk patients.

📚 Key Guidelines
📌 National Comprehensive Cancer Network Multiple Myeloma Guidelines
📌 International Myeloma Working Group recommendations
📌 Sanfilippo KM et al. J Clin Oncol. 2019 (IMPEDE VTE)

#MultipleMyeloma #Lenalidomide #Revlimid #VTE #Thromboprophylaxis #IMPEDE #SAVED #Hematology

[Benlazar S M A @smbenlazar]

INTENSIVE CHEMOTHERAPY IN COMBINATION WITH QUIZARTINIB VERSUS MIDOSTAURIN FOR FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA: A MULTICENTER COHORT STUDY https://t.co/g8V9rTfCfo #AML #leusm #EHA26

[Papa Heme @Papa_Heme]

A great oncologist once told me “the purpose of the heart is to pump the chemo to the cancer”

[Papa Heme @Papa_Heme]

Happy Mother's Day!

Stem cell in Spanish is "célula madre" which I find just perfect.

[BrickCenter @BrickCenter_]

Embiid pulled up to game 7 as the LeBron “down 3-1” meme 😭

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

We recently discussed t(11;14), t(4;14), and t(14;16).
Today—let’s simplify what matters most at the bedside:

👉 t(11;14) = “Leaky myeloma” 💧
👉 t(14;16) = “Sticky myeloma” 🧲

Yes… leaky vs sticky.

💧 t(11;14) — LEAKY
   •   CD56 negative → no adhesion
   •   Cells don’t stay in marrow → spill into blood
   •   PB involvement, EMD more common

🧠 Think:
No glue → no home → they wander

🎯 Biology: BCL-2 dependent
→ Target the protein (venetoclax)

🧲 t(14;16) — STICKY
   •   MAF → adhesion molecules + IL-6 signaling
   •   Early disease: locked in marrow niche
   •   Protected, hidden, therapy-resistant

🧠 Think:
Glued in place… safe for now

💥 Then evolution happens:
→ Lose niche dependence
→ Break out → aggressive EMD

🎯 The big difference:
   •   t(11;14) → escapes early
   •   t(14;16) → escapes late… and worse

⚡ Clinical translation:
   •   Leaky → target the vulnerability (BCL-2)
   •   Sticky → disrupt the environment + multi-agent therapy

🧠 If you remember one thing:

💧 If it leaks → shut the valve
🧲 If it sticks → break the niche

✍️ Dr Fun + G

#myeloma #hemetwitter